News

CURE8h
Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...
Amgen drug cuts small cell lung cancer death risk by 40%
Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...
MedPage Today8h
'Immediately Practice-Changing' Trial in Small Cell Lung Cancer
CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...
Roche’s Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says
The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.
Stocktwits on MSN1d
Amgen Says Its Drug Reduces Risk Of Death By 40% In Small Cell Lung Cancer: Retail’s Yet To Be Convinced
Shares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...
ascopubs.org5d
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor ...
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA ... patients with previous or current evidence of interstitial lung disease (ILD) were excluded. An Eastern ...
ascopubs.org6d
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): ...